Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731041 · ClinicalTrials.gov registry record · NA
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01731041 is a NA study that has completed, run by University of Florida. The registered enrollment target is 60 participants.
The verdict
NCT01731041, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke. Ticagrelor (Brilinta) keeps platelets from sticking together and it helps people from having a heart attack. The American College of Cardiology has recommended a combination of aspirin and Brilinta as one of the best treatments for the prevention of heart attacks, and death in patients who have had a heart attack or coronary stents. However, it is unknown if Brilinta may improve its work to keep platelets from sticking together giving a loading dose in patients already treated with Brilinta. A loading dose is a one-time increased dose of the same drug. The purpose of this study is to demonstrate whether the platelets of patients treated with Brilinta become less sticky when Brilinta is re-loaded.
Interventions
- DRUG Ticagrelor 90mg
- DRUG Ticagrelor 180mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01731041
The ClinicalTrials.gov registry entry for NCT01731041 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor 90mg is the first listed.
NCT01731041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01731041 about?
NCT01731041 is a clinical study titled "Impact of Ticagrelor Re-load on Pharmacodynamic Profiles". Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke. Ticagrelor (Brilinta) keeps platelets from sticking together and it helps peop...
What is the current status of trial NCT01731041?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01731041?
The interventions under investigation include: Ticagrelor 90mg (DRUG), Ticagrelor 180mg (DRUG).
Who is sponsoring clinical trial NCT01731041?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.